Today, Anal Cancer Foundation Scientific Advisory Board Member Dr. Joel Palefsky presented the Anal Cancer HSIL Outcomes Research (ANCHOR) study results at the prestigious CROI 2022 conference.

We learned that early detection and treatment of anal HSIL (anal precancer) reduces cancer progression by 57%.

“After 10 years of fighting for better prevention for anal cancer patients, we are thrilled to see the enormous progress made by Dr. Palefsky and his team,” said Tristan Almada, President of the Anal Cancer Foundation. “It is now clear that thousands of cancer cases can be prevented by finding and treating anal precancer. The next step is ensuring that early detection and treatment becomes standard of care so that we can end anal cancer.” 

Conceived by Dr. Joel Palefsky and supported through advocacy efforts by the Foundation, the ANCHOR Study was halted by the NIH early due to its success in reducing anal cancer incidence in people living with HIV. 

Congratulations to Dr. Palefsky and the entire ANCHOR team!